Episodes (Page 5)
✨
Triumvira Immunologics discusses TAC T cell Antigen Coupler.
✨
Poseida Therapeutics discusses challenges in allogeneic (allo) CGT development.
Kristin Yarema
✨
Aurion Biotech discusses cell therapy for corneal endothelial disease.
Greg Kunst
✨
Vittoria Biotherapeutics expands CAR T-cell therapy applications.
Nick Siciliano
✨
Astellas discusses gene therapy deal-making and collaborations.
Richard Wilson
✨
REGENXBIO discusses AAV gene therapy progress and scalability.
✨
ARM COO discusses 2023 Meeting on the Mesa highlights.
Rita Johnson-Greene
✨
Dr. Camillo Ricordi discusses cell and organ transplantation for T1D.
✨
Umoja Biopharma discusses allogeneic, in vivo CAR-T cell therapeutics.
Andrew Scharenberg
✨
FDA's Dr. Peter Marks discusses base and prime editing.
Peter Marks
✨
Lynelle Hoch discusses CAR-T's future and innovations.
Lynelle Hoch
✨
Rachel Haurwitz discusses genome editing evolution and potential.
✨
Stephan Krause discusses cell therapy focus areas for 2023.
Stephan Krause
✨
Dr. Francois Vigneault on RNA, AI, and synthetic biology in gene therapy.
Francois Vigneault
✨
Dr. Andrew Anzalone explains prime editing technology.
Andrew Anzalone
✨
Glenn Wright discusses navigating CMC challenges in CGT.
✨
Dr. Usman Azam shares insights on the state of cell and gene therapy.
Usman Azam
✨
Dr. Jak Knowles discusses targeting oncogenic drivers in solid tumors.
Jak Knowles
✨
Parviz Shamlou discusses Jefferson Institute for Bioprocessing (JIB).
Parviz Shamlou
✨
Dr. Shankar Ramaswamy on computational biology in gene therapy.
Shankar Ramaswamy